Compare ASTI & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTI | LITS |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 25.7M |
| IPO Year | 2014 | 2003 |
| Metric | ASTI | LITS |
|---|---|---|
| Price | $2.14 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 254.9K | ★ 930.1K |
| Earning Date | 11-09-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.23 | 13.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,398,149.00 | N/A |
| Revenue This Year | $987.62 | N/A |
| Revenue Next Year | $2,579.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 163.25 | N/A |
| 52 Week Low | $1.40 | $0.69 |
| 52 Week High | $9.87 | $2.26 |
| Indicator | ASTI | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 30.14 | 49.21 |
| Support Level | N/A | $1.06 |
| Resistance Level | $3.22 | $1.25 |
| Average True Range (ATR) | 0.19 | 0.11 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 5.86 | 13.51 |
Ascent Solar Technologies Inc is a solar technology company that manufactures and sells photovoltaic (PV) solar modules that are flexible, durable, and possess attractive power to weight and power to area performance. Its technology provides renewable power solutions to high-value production and specialty solar markets where traditional rigid solar panels are not suitable, including space power beaming, aerospace, satellites, near earth orbiting vehicles, fixed wing unmanned aerial vehicles (UAV), aquatic, terrestrial, and other weight-sensitive markets with transformational high quality, value added product applications. It operates in single PV segment that sells PV products and engineering services and currently, is selling it in North America.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.